Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
Deciphera(US:DCPH) Businesswire·2025-09-18 03:46公司动态 - 小野药品工业株式会社宣布其药物ROMVIMZA™ (vimseltinib)获得欧盟委员会批准 [1] - 该药物在欧盟获批用于治疗有症状的腱鞘巨细胞瘤成年患者 [1] - 适用患者需伴随临床相关的身体功能恶化且手术选择已用尽或会导致不可接受的后果 [1]